Posted by Michael Wonder on 13 Jun 2023
US FDA approves Bylvay for patients living with cholestatic pruritus due to Alagille syndrome
13 June 2023 - Immediate US commercial launch and availability for eligible patients.
Ipsen today announced that the US FDA has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome.
